Fujisawa saw first-half equipment sales rise:
This article was originally published in Clinica
Executive Summary
In the six months to the end of September 1995, the medical equipment and supplies division of Japanese pharmaceutical company Fujisawa was the only business sector showing growth compared with the previous year. Medical equipment turnover rose 20% to ¥45 million ($9 million). This represents around 1% of Fujisawa's total sales of Yen106,367 million, which were down 10%. The company attributes the growth in medical equipment sales partly to reagents which are produced by US company PharMingen.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.